타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cemiplimab |
Overview Company | Regeneron / Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Solid Tumor |
Overview Indication | Breast Neoplasms; Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | unique and favorable safety profile with no reported grade 4 or 5 immune-related adverse events after more than 2 years of fol |
Positioning Known limitation | resistance to immune checkpoint blockade |
MoA Mechanism | , clinical trial data, and its role compared to other PD-1/PD-L1 inhibitors, such as pembrolizumab and cemiplimab |
MoA Biomarker | biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable c |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cemiplimab |
Overview Company | Regeneron / Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Solid Tumor |
Overview Indication | Breast Neoplasms; Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | unique and favorable safety profile with no reported grade 4 or 5 immune-related adverse events after more than 2 years of fol |
Positioning Known limitation | resistance to immune checkpoint blockade |
MoA Mechanism | , clinical trial data, and its role compared to other PD-1/PD-L1 inhibitors, such as pembrolizumab and cemiplimab |
MoA Biomarker | biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable c |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교